Vertex announces new drug submission for investigational triple combination medicine for the treatment of cystic fibrosis has been accepted for priority review by Health Canada

28 December 2020 - Vertex Pharmaceuticals Incorporated today announced its New Drug Submission for Trikafta, Vertex’s investigational triple combination medicine, ...

Read more →

Health Canada grants priority review status for Heron Therapeutics' new drug submission for HTX-011 for management of post-operative pain

3 December 2019 - Heron Therapeutics today announced that Heron's new drug submission for HTX-011 for the management of postoperative pain ...

Read more →

Medexus granted priority review status for Gliolan by Health Canada

19 November 2019 - Medexus Pharmaceuticals today announced that Health Canada has granted priority review status for the new drug ...

Read more →

Alnylam Pharmaceuticals receives priority review in Canada for patisiran, an investigational RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy

24 September 2018 - Health Canada grants priority review to promising medicines intended for the treatment of serious, debilitating or life-threatening ...

Read more →

Health Canada accepts Mitsubishi Tanabe Pharma Corporation's NDS filing for edaravone to treat ALS, grants priority review

9 April 2018 - Mitsubishi Tanabe Pharma Canada launched in Toronto to prepare business operations. ...

Read more →

Janssen announces Imbruvica (ibrutinib) as the first approved treatment for chronic graft-versus-host disease granted by Health Canada priority review

30 October 2017 - Approval provides a much-needed option for patients who develop this life-threatening condition following stem cell transplant. ...

Read more →

Raptor's Procysbi new drug submission accepted by Health Canada with priority review

21 March 2016 - Raptor Pharmaceutical Corporation today announced that Health Canada has accepted for review its New Drug Submission for ...

Read more →